Literature DB >> 3280497

Phenylpropanolamine and other over-the-counter vasoactive compounds.

E L Bravo1.   

Abstract

Phenylpropanolamine is a sympathomimetic amine that shares structural similarities with amphetamine and ephedrine. It increases blood pressure primarily by increasing peripheral vascular resistance. This effect is the result of alpha-adrenergic agonist activity largely from both direct stimulation of adrenergic receptors and release of neuronal norepinephrine. As such, it has the potential to interact with other drugs to produce toxic reactions, especially in treated hypertensive patients. Complications have occurred with single oral doses that suggest some normal subjects may be more sensitive to the drug than others. The incidence of serious complications in the general population is small but could be much higher in susceptible individuals (e.g., cardiomyopathic and hypertensive patients). The availability of high-dose phenylpropanolamine-containing preparations without medical supervision is potentially dangerous, and certain restrictions should be imposed on such preparations.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3280497     DOI: 10.1161/01.hyp.11.3_pt_2.ii7

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  5 in total

Review 1.  What do you do when the blood pressure is up? An approach to the known hypertensive who has an elevated blood pressure.

Authors:  R L Schiff; M H Cohen; A Balson
Journal:  J Gen Intern Med       Date:  1991 Jan-Feb       Impact factor: 5.128

Review 2.  Optimum pharmacological management of chronic rhinitis.

Authors:  F E Simons; K J Simons
Journal:  Drugs       Date:  1989-08       Impact factor: 9.546

3.  Necroptosis-like Neuronal Cell Death Caused by Cellular Cholesterol Accumulation.

Authors:  Takeshi Funakoshi; Toshihiko Aki; Masateru Tajiri; Kana Unuma; Koichi Uemura
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

Review 4.  Cardiovascular effects of atomoxetine in children, adolescents, and adults.

Authors:  Joachim F Wernicke; Douglas Faries; Donald Girod; Jeffrey Brown; Haitao Gao; Douglas Kelsey; Humberto Quintana; Robert Lipetz; David Michelson; John Heiligenstein
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 5.  Acute rhinosinusitis in adults: an update on current management.

Authors:  Ajmal Masood; Ioannis Moumoulidis; Jaan Panesar
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.